Clozapine and Metabolites Quantitative


Abbrev Code:CLOZPM   
Order Code:LAB6979Order Name:Clozapine and Metabolites Quantitative
Synonyms:Clozaril
Methodology:Liquid chromatography/Tandem mass spectrometry
CPT Codes: 80159 x1
Turnaround Time:Specimens are sent to reference laboratory Mon-Sat; results are reported within 1-3 days.
Compliance:

For tests developed and validated by ARUP (previously referred to as Compliance Statement B, C or D). This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.



Collection Instructions

Specimen:Blood
Optimal Volume:2 mL
Minimum\Peds Volume:1.2 mL
Container:Red (no gel)
Alternate Containers: Purple (EDTA)
Collection Instructions:Usual sampling time is immediately prior to next dose (trough).
Causes for Rejection:Whole blood. Gel separator tubes. Light blue (citrate) or yellow (SPS or ACD solution).


Processing and Shipping

Specimen Processing:Within 2 hours of collection, centrifuge and aliquot 1 mL, 0.5 mL minimum. Store refrigerated.
Shipping Instructions:Ship refrigerated.
Stability:After separation from cells: 5 weeks at room temperature; 2 months refrigerated (preferred), or frozen.
Test Performed at or Referral Lab Lab Sendouts  (ARUP)
Referral Lab number:2013433


Interpretive

Therapeutic Range:Therapeutic ranges are not well established. Clozapine is metabolized to norclozapine and clozapine-N-oxide. Clozapine concentrations between 100 and 700 ng/mL may correlate more with a clinical response; however, non-responsiveness may also occur within this range. For refractory schizophrenia, clozapine concentrations greater than 350 ng/mL are suggested to achieve a therapeutic response. Toxicity: Toxic ranges are not well established. Serum/plasma concentrations greater than or equal to 1500 ng/mL (clozapine, norclozapine and clozapine-N-oxide combined) may cause drug-induced agranulocytosis. Stevens-Johnson syndrome, seizures, hypotension, cardiovascular abnormalities, drowsiness and death.


Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 2924"